Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Circulerend tumor-DNA toont maanden eerder dan scan of kankertherapie effectief is
nov 2023 | Dermato-oncologie, Uro-oncologie